Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

The Future for Laboratory Technology Unveiled

By Labmedica International staff writers
Posted on 19 Mar 2012
Print article
Biomedical laboratories need to be able to deal with a high throughput of samples while reliably documenting each step in the testing process.

The fact that it takes so long for laboratories to analyze samples is in no small part due to all the cumbersome paperwork as each sample must be accompanied by meticulous records.

At the Fraunhofer Institute for Biomedical Engineering (IBMT; St. Ingbert, Germany) scientists are developing a fully automated approach to testing, with a particular emphasis on automating the documenting of samples. The main aim is to enable sample data to be processed automatically. A tiny microchip is embedded in the plastic of the test tube and used to store all relevant information, such as when and where a sample is from and the patient's name. In the past, test tubes would be written on by hand; more recently, the data has been stored in a barcode for easy scanning.

When the test tube is placed into an analyzer, the equipment can record details on the embedded chip of exactly what went on in the analysis. This means the test tube itself carries the sample's entire history, with no need for technicians to write up a laborious report including the patient's details, the results of the analysis and the testing methods employed. Scientists at IBMT are working together with Soventec GmbH (Dannewerk, Germany) to develop the LabOS laboratory management system. Working with LabOS, as soon as a test tube is placed in a reader, a screen displays data on the sample's history and also what the next steps are without the need for any paperwork.

Daniel Schmitt, Dipl. Phys., a project leader for the IBMT, said, "Usually, samples are accompanied by a report slip. Alternatively, the laboratory will know to expect a sample when it receives an e-mail containing all the necessary information. With test tube chips, the sample and the information are inseparably linked, and there is no way for information to go astray." For some time now, the project partners have been able to demonstrate just how well all this technology works together thanks to a mobile laboratory. Housed in a truck that is traveling all over South Africa, it is mainly working to diagnose AIDS and tuberculosis. The scientists showed the effectiveness of their concept at the MEDTEC Europe trade fair in Stuttgart, Germany from March 13 to 15, 2012.

Related Links:

Fraunhofer Institute for Biomedical Engineering
Soventec GmbH



Print article

Channels

Clinical Chemistry

view channel
Image: Dried blood spots are used to screen newborns for a number of rare inherited conditions. A new dried blood spot screening test has been developed for Niemann-Pick type C, a rare neurodegenerative condition that usually is not diagnosed until after damage to brain cells has begun (Photo courtesy of Washington University School of Medicine).

Newborn Screening Test Developed For Deadly Neurological Disorder

A newborn screening test has been introduced that identifies infants with Niemann-Pick disease type C, an often fatal condition in which cholesterol builds up and eventually destroys brain cells.... Read more

Genetic Tests

view channel
Image: The BioMek FXP automation workstation (Photo courtesy of Beckman Coulter).

Innovative Gene Testing Technology Finds Cancer Risks

A new method has been developed for identifying mutations and prioritizing variants in breast and ovarian cancer genes, which will not only reduce the number of possible variants for doctors to investigate,... Read more

Pathology

view channel
Image: A photomicrograph of an abnormal Pap smear showing changes consistent with Human Papilloma Virus (HPV) and Mild Dysplasia. Note the irregular perinuclear cytoplasmic clearing, which is the key characteristic of identifying HPV visually on a Pap smear (Photo courtesy of Dr. Cynthia D Booth, MD).

Combining Two Diagnostic Tests Drastically Reduces Cancer Miss Rates

The Papanicolaou (Pap) test is recommended for women between 21 and 65 years old as a screening test for cervical cancer. Women 30 and older who are negative on co-testing may wait as long as five years... Read more

Industry News

view channel

R-Biopharm and Merck Partner on Companion Diagnostics

R-Biopharm AG (Darmstadt, Germany) and Merck KGaA (Darmstadt, Germany) have entered into an agreement that constitutes their first collaboration, which will initially focus on developing and launching companion diagnostics. Companion diagnostics play a central role in personalized medicine by helping to find specific... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.